Tags

Type your tag names separated by a space and hit enter

A 10-year outcomes evaluation of mucinous and signet-ring cell carcinoma of the colon and rectum.
Dis Colon Rectum. 2005 Jun; 48(6):1161-8.DC

Abstract

PURPOSE

Most studies examining mucinous or signet-ring cell colorectal cancers are single institution reports. This study used a national cancer registry to analyze the epidemiology and survival outcomes of these two subtypes of colorectal cancer compared with adenocarcinoma tumors.

METHODS

All patients diagnosed with mucinous (n = 16,991), signet-ring cell (n = 1,522), or adenocarcinoma (n = 146,115) colorectal cancer in the Surveillance, Epidemiology, and End Results database (1991-2000) were evaluated. Analyses were performed to obtain age-adjusted incidence rates, stage at presentation, tumor grade, and five-year relative survival for each subtype.

RESULTS

Mucinous were slightly more common in females (53.4 percent). Incidence rates per 100,000 persons were: mucinous, 5.5; signet-ring cell, 0.6; and adenocarcinoma 46.6. The annual percent change during ten years was stable for mucinous, increased for signet-ring cell (4.8 percent; P < 0.05), and decreased for adenocarcinoma (-1.1 percent; P < 0.05). Fewer mucinous (18 percent) and signet-ring cell (21 percent) tumors were located in the rectum compared with adenocarcinoma (29 percent). Signet-ring cell presented at later stage (III/IV, 80.9 percent) more often than mucinous (52.8 percent) and adenocarcinoma (49.5 percent), and also had worse tumor grade (high grade: signet-ring cell, 73.5 percent; mucinous, 20.9 percent; adenocarcinoma, 17.5 percent). Relative five-year survival was worse for signet-ring cell than mucinous or adenocarcinoma.

CONCLUSIONS

We present a large population-based review of colorectal cancer subtypes by analyzing national data from the past decade. Although the incidence of colorectal adenocarcinoma is decreasing in the United States, mucinous and signet-ring cell subtypes are stable and increasing, respectively. Importantly, it seems that the signet-ring cell subtype has worse outcomes, whereas survival rates for mucinous tumors are similar to adenocarcinomas.

Authors+Show Affiliations

Kang H
Department of Surgery, Daehang Hospital, Seoul, Korea.
O'Connell JB
No affiliation info available
Maggard MA
No affiliation info available
Sack J
No affiliation info available
Ko CY
No affiliation info available

MeSH

Adenocarcinoma, MucinousAdultAgedAged, 80 and overCarcinoma, Signet Ring CellColonic NeoplasmsFemaleHumansIncidenceMaleMiddle AgedNeoplasm StagingRectal NeoplasmsSEER ProgramSurvival RateTreatment OutcomeUnited States

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15868237

Citation

Kang, Hakjung, et al. "A 10-year Outcomes Evaluation of Mucinous and Signet-ring Cell Carcinoma of the Colon and Rectum." Diseases of the Colon and Rectum, vol. 48, no. 6, 2005, pp. 1161-8.
Kang H, O'Connell JB, Maggard MA, et al. A 10-year outcomes evaluation of mucinous and signet-ring cell carcinoma of the colon and rectum. Dis Colon Rectum. 2005;48(6):1161-8.
Kang, H., O'Connell, J. B., Maggard, M. A., Sack, J., & Ko, C. Y. (2005). A 10-year outcomes evaluation of mucinous and signet-ring cell carcinoma of the colon and rectum. Diseases of the Colon and Rectum, 48(6), 1161-8.
Kang H, et al. A 10-year Outcomes Evaluation of Mucinous and Signet-ring Cell Carcinoma of the Colon and Rectum. Dis Colon Rectum. 2005;48(6):1161-8. PubMed PMID: 15868237.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A 10-year outcomes evaluation of mucinous and signet-ring cell carcinoma of the colon and rectum. AU - Kang,Hakjung, AU - O'Connell,Jessica B, AU - Maggard,Melinda A, AU - Sack,Jonathan, AU - Ko,Clifford Y, PY - 2005/5/4/pubmed PY - 2005/7/13/medline PY - 2005/5/4/entrez SP - 1161 EP - 8 JF - Diseases of the colon and rectum JO - Dis Colon Rectum VL - 48 IS - 6 N2 - PURPOSE: Most studies examining mucinous or signet-ring cell colorectal cancers are single institution reports. This study used a national cancer registry to analyze the epidemiology and survival outcomes of these two subtypes of colorectal cancer compared with adenocarcinoma tumors. METHODS: All patients diagnosed with mucinous (n = 16,991), signet-ring cell (n = 1,522), or adenocarcinoma (n = 146,115) colorectal cancer in the Surveillance, Epidemiology, and End Results database (1991-2000) were evaluated. Analyses were performed to obtain age-adjusted incidence rates, stage at presentation, tumor grade, and five-year relative survival for each subtype. RESULTS: Mucinous were slightly more common in females (53.4 percent). Incidence rates per 100,000 persons were: mucinous, 5.5; signet-ring cell, 0.6; and adenocarcinoma 46.6. The annual percent change during ten years was stable for mucinous, increased for signet-ring cell (4.8 percent; P < 0.05), and decreased for adenocarcinoma (-1.1 percent; P < 0.05). Fewer mucinous (18 percent) and signet-ring cell (21 percent) tumors were located in the rectum compared with adenocarcinoma (29 percent). Signet-ring cell presented at later stage (III/IV, 80.9 percent) more often than mucinous (52.8 percent) and adenocarcinoma (49.5 percent), and also had worse tumor grade (high grade: signet-ring cell, 73.5 percent; mucinous, 20.9 percent; adenocarcinoma, 17.5 percent). Relative five-year survival was worse for signet-ring cell than mucinous or adenocarcinoma. CONCLUSIONS: We present a large population-based review of colorectal cancer subtypes by analyzing national data from the past decade. Although the incidence of colorectal adenocarcinoma is decreasing in the United States, mucinous and signet-ring cell subtypes are stable and increasing, respectively. Importantly, it seems that the signet-ring cell subtype has worse outcomes, whereas survival rates for mucinous tumors are similar to adenocarcinomas. SN - 0012-3706 UR - https://www.unboundmedicine.com/medline/citation/15868237/A_10_year_outcomes_evaluation_of_mucinous_and_signet_ring_cell_carcinoma_of_the_colon_and_rectum_ DB - PRIME DP - Unbound Medicine ER -